Patients with terminal leukemia who were not responding to treatment now have hope for a cure thanks to revumenib, a new experimental medication. In a long-awaited clinical trial in the United States, this medicine fully eradicated cancer in one-third of … [Read more...] about Revumenib: the breakthrough pill curing leukemia in a third of patients
cancer treatment
Universal cancer immunotherapy may be possible through protein engineering
Scientists at ETH Zurich have made significant progress in developing a ready-to-use immunotherapy treatment for cancer. A synthetic protein modification can allow immune cells from any donor to be delivered to any patient without the risk of an adverse immunological … [Read more...] about Universal cancer immunotherapy may be possible through protein engineering
Study shows how genetically engineered bacteria can find and destroy tumors
Cancer tumors are very effective at avoiding the immune system, making intervention difficult. A common gut bacterium has been genetically altered to seek out and destroy cancer tumors from within, as shown in a new study. Why are tumors so hard to treat? Tumors can thrive by … [Read more...] about Study shows how genetically engineered bacteria can find and destroy tumors
Rectal cancer trial sees tumor disappear in all patients
A drug study involving people with rectal cancer has remarkably eradicated the tumor in all 18 patients. Though small, the trial astounded practitioners in the field, touting the results as an unprecedented achievement in cancer treatment, reports The New York Times. Cancer … [Read more...] about Rectal cancer trial sees tumor disappear in all patients
Novel blood cancer treatment effective in three-fourths of trial patients
According to new findings from an ongoing Phase 1/2 clinical research trial, a novel investigational immunotherapy resulted in successful response rates for 73 percent of patients with multiple myeloma, a lethal form of blood cancer. Based on these encouraging findings, an … [Read more...] about Novel blood cancer treatment effective in three-fourths of trial patients